Chiusura precedente | 5,2500 |
Aperto | 5,1400 |
Denaro | 4,7700 x 100 |
Lettera | 4,8300 x 400 |
Min-Max giorno | 4,8000 - 5,2000 |
Intervallo di 52 settimane | 3,6600 - 9,0650 |
Volume | |
Media Volume | 683.764 |
Capitalizzazione | 502,683M |
Beta (5 anni mensile) | 0,79 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,4300 |
Prossima data utili | 02 mag 2024 - 06 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 14,50 |
Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference (New York, New York) Monday, September 11, 2023 at 4:55 p.m. ET, fireside chat H.C. Wainwright 25th Annual Global Investment Conference (New York, New York) Tuesday, September 12, 2023 a
Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC) Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments p